SynthesisWorld journal of urology2026
Retroperitoneal lymph node dissection for growing teratoma syndrome in testicular cancer: a systematic review of surgical outcomes.
Synthesis in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Isolated Cervical Seminoma Without Testicular or Mediastinal Primary: A Rare Extragonadal Germ Cell Tumor Presentation.Case reports in oncological medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGrowing Teratoma Syndrome (GTS) is a rare entity occurring in patients with non-seminomatous germ cell tumours (NSGCT) following chemotherapy. GTS is resistant to chemotherapy and radiotherapy, making retroperitoneal lymph node dissection (RPLND) the mainstay of treatment. This review aims to synthesize evidence on the surgical management and oncological outcomes of retroperitoneal GTS.
methodsA systematic review was conducted in accordance with PRISMA guidelines and registered in PROSPERO (CRD420251233173). PubMed and Embase were searched from inception to November 2025. Risk of bias was assessed using the ROBINS-I tool.
resultsFifteen studies comprising 156 patients with NSGCT-associated retroperitoneal GTS treated with RPLND were included. The reported incidence ranged from 2.8% to 7.6%. Median patient age across studies was 16–38 years. Mixed NSGCT was present in 73–100% of orchidectomy specimens, with a teratoma component identified in 40–100%. The interval to RPLND ranged from 2 to 30 months and median operative time ranged from 160 to 432 min, and estimated blood loss from 225 to 2500 mL. Adjunctive procedures were required in 10–100% of patients, and postoperative complications occurred in 12.5–44%, with Clavien-Dindo ≥ III complications in 12.5–25%. Median length of hospital stay ranged from 5 to 15 days. Disease-free survival varied between 41.7% and 100%, and overall survival between 73.7% and 100% with follow-up ranging from 8 to 103 months.
conclusionsRPLND is a complex procedure with effective oncological outcomes for GTS. Multicentric registries are needed for generating high-quality standardised data.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.